Chronic Inflammatory Demyelinating Polyneuropathy

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a neurological disorder characterized by progressive weakness and impaired sensory function in the arms and legs.

Featured Video

European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second Revision

CIDP

Watch Dr. Peter Van den Bergh, lead author, take you through the highlights of the guideline.

Videos about CIDP

VIEW ALL VIDEOS

Consistency Over Time of Strength and Disability Measurements in Patients with CIDP on Stable IgG Therapy

Mel Berger, MD, PhD

Medical Research Strategy, CSL Behring

8:25 MIN

CIDP

Hear the results of a study to understand wear-off effects in CIDP patients during IVIg therapy.

DOWNLOAD PDF

Pathogenesis and Mechanism of Action of Inflammatory Neuropathies

Richard A. Lewis, MD

Cedars-Sinai Medical Center, Los Angeles, CA, USA

13:53 MIN

CIDP
GBS
MMN

Find out what pathogenic processes are involved in acute and chronic inflammatory neuropathies, including GBS, CIDP, and MMN.

DOWNLOAD PDF

Fatigue in CIDP

Karissa Gable, MD

Duke University Medical Center in Durham, North Carolina

09:29 MIN

CIDP

Engage in a presentation on the comparison between active and remission disease states in CIDP.

DOWNLOAD PDF

Incidence of GBS and CIDP Following Influenza Vaccination

Peter Donofrio, MD

Vanderbilt University Medical Center, Nashville, TN, USA

25:18 MIN

CIDP
GBS

Gain an understanding of the existing surveillance data, studies and facts associated with the influenza vaccine as it relates to GBS and CIDP.

DOWNLOAD PDF

NOW PLAYING

8:25

Consistency Over Time of Strength and Disability Measurements in Patients with CIDP on Stable IgG Th...

Hear the results of a study to understand wear-off effects in CIDP patients during IVIg therapy.

NOW PLAYING

13:53

Pathogenesis and Mechanism of Action of Inflammatory Neuropathies

Find out what pathogenic processes are involved in acute and chronic inflammatory neuropathies, including GBS, CIDP, and MMN.

NOW PLAYING

09:29

Fatigue in CIDP

Engage in a presentation on the comparison between active and remission disease states in CIDP.

NOW PLAYING

25:18

Incidence of GBS and CIDP Following Influenza Vaccination

Gain an understanding of the existing surveillance data, studies and facts associated with the influenza vaccine as it relates to GBS and CIDP.

Our Experts on CIDP

VIEW ALL EXPERTS

Nabil Moumane, MD

Medical Affairs and Pharmacology, CSL Behring

Nabil Moumane, MD

Medical Affairs and Pharmacology, CSL Behring

CIDP
MMN

Nabil Moumane is the Director of Medical Affairs and Pharmacology at CSL Behring.

Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

CIDP

Dr Michael Lunn is a Consultant Neurologist, Clinical Lead in Neuroimmunology and Honorary Senior Lecturer at the National Hospital for Neurology and Neurosurgery.

Vera Bril, BSc, FRCPC, MD

University of Toronto,Toronto, Canada

Vera Bril, BSc, FRCPC, MD

University of Toronto,Toronto, Canada

CIDP

Vera Bril is a Professor of Medicine (Neurology) at the University of Toronto, Director of Neurology at University Health Network and Mount Sinai Hospital and the Krembil Family Chair in Neurology.

Mel Berger, MD, PhD

Medical Research Strategy, CSL Behring

Mel Berger, MD, PhD

Medical Research Strategy, CSL Behring

CIDP

Mel Berger is a Senior Director, Medical Research Strategy at CSL and Adjunct Professor of Pediatrics and Pathology, Case Western Reserve University. He earned his undergraduate, medical and PhD (in Biochemistry) degrees at Case Western Reserve University in Cleveland.

What is Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP)?

What are the symptoms of CIDP?

How is CIDP treated?